Galecto Biotech

Galecto Biotech AB (Lund, Sweden) is an early-stage orphan drug development company focusing on novel therapeutics for fibrosis and inflammatory-related diseases, including the lung disease Idiopathic Pulmonary Fibrosis (IPF). The lead program is in clinical development and addresses a novel therapeutic target for IPF called Galectin-3.
Søren Lemonius, MSc

Managing General Partner

Mobile: +45 40 81 48 89